Form 8-K - Current report:
SEC Accession No. 0001193125-26-009894
Filing Date
2026-01-12
Accepted
2026-01-12 09:00:09
Documents
53
Period of Report
2026-01-12
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d28401d8k.htm   iXBRL 8-K 27881
2 EX-99.1 d28401dex991.htm EX-99.1 18889
3 EX-99.2 d28401dex992.htm EX-99.2 50019
7 GRAPHIC g28401ex99_2p10g1.jpg GRAPHIC 260133
8 GRAPHIC g28401ex99_2p11g1.jpg GRAPHIC 291894
9 GRAPHIC g28401ex99_2p12g1.jpg GRAPHIC 275854
10 GRAPHIC g28401ex99_2p13g1.jpg GRAPHIC 399703
11 GRAPHIC g28401ex99_2p14g1.jpg GRAPHIC 328776
12 GRAPHIC g28401ex99_2p15g1.jpg GRAPHIC 186299
13 GRAPHIC g28401ex99_2p16g1.jpg GRAPHIC 263431
14 GRAPHIC g28401ex99_2p17g1.jpg GRAPHIC 297672
15 GRAPHIC g28401ex99_2p18g1.jpg GRAPHIC 244114
16 GRAPHIC g28401ex99_2p19g1.jpg GRAPHIC 315633
17 GRAPHIC g28401ex99_2p1g1.jpg GRAPHIC 421787
18 GRAPHIC g28401ex99_2p20g1.jpg GRAPHIC 333314
19 GRAPHIC g28401ex99_2p21g1.jpg GRAPHIC 292082
20 GRAPHIC g28401ex99_2p22g1.jpg GRAPHIC 318699
21 GRAPHIC g28401ex99_2p23g1.jpg GRAPHIC 335453
22 GRAPHIC g28401ex99_2p24g1.jpg GRAPHIC 313933
23 GRAPHIC g28401ex99_2p25g1.jpg GRAPHIC 244404
24 GRAPHIC g28401ex99_2p26g1.jpg GRAPHIC 260453
25 GRAPHIC g28401ex99_2p27g1.jpg GRAPHIC 233897
26 GRAPHIC g28401ex99_2p28g1.jpg GRAPHIC 291485
27 GRAPHIC g28401ex99_2p29g1.jpg GRAPHIC 319448
28 GRAPHIC g28401ex99_2p2g1.jpg GRAPHIC 796750
29 GRAPHIC g28401ex99_2p30g1.jpg GRAPHIC 273770
30 GRAPHIC g28401ex99_2p31g1.jpg GRAPHIC 383727
31 GRAPHIC g28401ex99_2p32g1.jpg GRAPHIC 376085
32 GRAPHIC g28401ex99_2p33g1.jpg GRAPHIC 209749
33 GRAPHIC g28401ex99_2p34g1.jpg GRAPHIC 392835
34 GRAPHIC g28401ex99_2p35g1.jpg GRAPHIC 243216
35 GRAPHIC g28401ex99_2p36g1.jpg GRAPHIC 240746
36 GRAPHIC g28401ex99_2p37g1.jpg GRAPHIC 204179
37 GRAPHIC g28401ex99_2p38g1.jpg GRAPHIC 212598
38 GRAPHIC g28401ex99_2p3g1.jpg GRAPHIC 282188
39 GRAPHIC g28401ex99_2p4g1.jpg GRAPHIC 220494
40 GRAPHIC g28401ex99_2p5g1.jpg GRAPHIC 270035
41 GRAPHIC g28401ex99_2p6g1.jpg GRAPHIC 269952
42 GRAPHIC g28401ex99_2p7g1.jpg GRAPHIC 369445
43 GRAPHIC g28401ex99_2p8g1.jpg GRAPHIC 256915
44 GRAPHIC g28401ex99_2p9g1.jpg GRAPHIC 271702
45 GRAPHIC g28401g0109152426648.jpg GRAPHIC 5169
  Complete submission text file 0001193125-26-009894.txt   16092960

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA syre-20260112.xsd EX-101.SCH 2830
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE syre-20260112_lab.xml EX-101.LAB 18755
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syre-20260112_pre.xml EX-101.PRE 11696
55 EXTRACTED XBRL INSTANCE DOCUMENT d28401d8k_htm.xml XML 3776
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Spyre Therapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 26524890
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)